1. DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn's disease. (25th January 2019) Authors: Reinisch, W; Jang, B I; Borzan, V; Lahat, A; Pukitis, A; Osipenko, M; Mostovoy, Y; Schreiber, S; Ben-Horin, S; Lee, S J; Suh, J H; Lee, S G; Lee, J H; Ye, B D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P826 Unexplained higher frequency of mutant thiopurine S-methyltransferase genotypes in inflammatory bowel disease patients of Latvia population. (25th January 2019) Authors: Zalizko, P; Stefanovics, J; Erts, R; Rovite, V; Klovins, J; Pukitis, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗